MedTrace Logo

Endostatin in Combination With Oxaliplatin and Radiotherapy in Esophageal Cancer Patients.

NCT02745561 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2016-04-20

No results posted yet for this study

Summary

Endostatin inhibits the pro-angiogenic action of basic fibroblast growth factor and vascular endothelial growth factor in esophageal cancer.This study aims at assessing the efficacy and safety of endostatin combined with concurrent chemoradiotherapy with Oxaliplatin in esophageal cancer patients.

Conditions

  • Esophageal Cancer
  • Endostatin

Interventions

DRUG

Endostatins

Endostatin will be administered at a dose of 7.5 mg/m2/day concurrent with radiotherapy.

DRUG

Oxaliplatin

Oxaliplatin (135mg/m², d1) will be administered on Day 1 and Day 29 of radiotherapy.

RADIATION

Radiotherapy

Radiotherapy will be delivered with a daily fraction of 2.0 Gy to a total dose of 60 Gy over 6 weeks.

Sponsors & Collaborators

  • Hangzhou Cancer Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-31
Primary Completion
2017-12-31
Completion
2018-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02745561 on ClinicalTrials.gov